Tag: preclinical
-
Bio-Electric Regeneration Company Adds $8M in Seed Funds
A start-up enterprise, spun-off from Tufts University labs, creating bio-electrical treatments for regenerating limbs and tissue, is raising $8 million in new seed funds.
-
Biotech Drug Shown to Kill Prostate Tumor Cells
Tests with lab mice show low doses of an experimental oral drug can selectively kill prostate cancer cells while not affecting surrounding healthy tissue.
-
Implanted Tissue Shown to Produce Thyroid Hormones
In a preclinical test, thyroid tissue earlier removed from lab animals was re-implanted in a protective pouch, which generates production of key hormones by the animals.
-
Biotech, Academic Lab Partner on Microbiome-Safe Products
A biotechnology company creating products for gut health and a university immunology lab are evaluating cleaning products for potential damage to human protective tissues.
-
Nasal Spray Vaccine Shown to Stop Gonorrhea Infections
A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine.
-
Nanotech Enzyme Process Boosts T-Cell Cancer Therapies
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells.
-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Implanted Organoid Connects to Brain, Reacts to Visual Cues
Engineers and neuroscientists developed a circuit that in lab mice connects implanted lab-grown brain tissue to the brain’s cognitive center and responds to visual stimuli.
-
Bone Regeneration Experiment Begun on Space Station
An experiment is underway testing a bone repair biomaterial in lab mice under weightless conditions on the International Space Station.
-
Gut-Brain Meds Developer Going Public in Merger
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, in a deal expected to…